I

Imexpharm Corp
VN:IMP

Watchlist Manager
Imexpharm Corp
VN:IMP
Watchlist
Price: 50 200 VND 0.2% Market Closed
Market Cap: 7.7T VND

Relative Value

The Relative Value of one IMP stock under the Base Case scenario is 43 014.5 VND. Compared to the current market price of 50 200 VND, Imexpharm Corp is Overvalued by 14%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

IMP Relative Value
Base Case
43 014.5 VND
Overvaluation 14%
Relative Value
Price
I
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
17
vs Industry
36
Median 3Y
2.3
Median 5Y
1.4
Industry
2.6
Forward
3
vs History
19
vs Industry
20
Median 3Y
19.7
Median 5Y
10.3
Industry
21.7
Forward
22.1
vs History
vs Industry
14
Median 3Y
5.7
Median 5Y
8.7
Industry
16.6
vs History
4
vs Industry
12
Median 3Y
16.5
Median 5Y
13.7
Industry
22.5
vs History
11
vs Industry
23
Median 3Y
2.2
Median 5Y
1.1
Industry
2.3
vs History
14
vs Industry
37
Median 3Y
2.3
Median 5Y
1.4
Industry
2.9
Forward
3
vs History
17
vs Industry
27
Median 3Y
6
Median 5Y
3.4
Industry
5.5
vs History
17
vs Industry
27
Median 3Y
10.6
Median 5Y
6.1
Industry
13.1
Forward
12.9
vs History
19
vs Industry
25
Median 3Y
13.5
Median 5Y
7.5
Industry
16.6
Forward
16.4
vs History
vs Industry
14
Median 3Y
4.7
Median 5Y
8.2
Industry
15.8
vs History
vs Industry
8
Median 3Y
4.9
Median 5Y
7.3
Industry
19.1
vs History
14
vs Industry
24
Median 3Y
2.1
Median 5Y
1
Industry
1.9

Multiples Across Competitors

IMP Competitors Multiples
Imexpharm Corp Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
VN
Imexpharm Corp
VN:IMP
7.7T VND 3.2 24.2 13.8 17
US
Eli Lilly and Co
NYSE:LLY
955.6B USD 16.1 51.9 34.9 37.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
485.9B USD 5.3 19.3 15.8 20.5
CH
Roche Holding AG
SIX:ROG
247.6B CHF 4 26.3 11.3 13.1
UK
AstraZeneca PLC
LSE:AZN
210.8B GBP 4.8 29.9 108.2 158.4
CH
Novartis AG
SIX:NOVN
205.5B CHF 4.6 17.7 11.3 14.6
US
Merck & Co Inc
NYSE:MRK
248B USD 3.9 13 9.3 11
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.4 13.2 9.3 10.8
IE
Endo International PLC
LSE:0Y5F
202.5B USD 87.3 -69.3 321.2 805.4
US
Pfizer Inc
NYSE:PFE
148B USD 2.4 15.1 7.6 10.4
P/E Multiple
Earnings Growth PEG
VN
I
Imexpharm Corp
VN:IMP
Average P/E: 23.4
24.2
16%
1.5
US
Eli Lilly and Co
NYSE:LLY
51.9
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.3
29%
0.7
CH
Roche Holding AG
SIX:ROG
26.3
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
29.9
38%
0.8
CH
Novartis AG
SIX:NOVN
17.7
17%
1
US
Merck & Co Inc
NYSE:MRK
13
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.2
4%
3.3
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -69.3 N/A N/A
US
Pfizer Inc
NYSE:PFE
15.1
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
VN
I
Imexpharm Corp
VN:IMP
Average EV/EBITDA: 399
13.8
15%
0.9
US
Eli Lilly and Co
NYSE:LLY
34.9
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
15.8
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.3
4%
2.8
UK
AstraZeneca PLC
LSE:AZN
108.2
10%
10.8
CH
Novartis AG
SIX:NOVN
11.3
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.3
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9.3
2%
4.6
IE
E
Endo International PLC
LSE:0Y5F
321.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
1%
7.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
VN
I
Imexpharm Corp
VN:IMP
Average EV/EBIT: 1 709.2
17
19%
0.9
US
Eli Lilly and Co
NYSE:LLY
37.4
36%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.5
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.1
5%
2.6
UK
AstraZeneca PLC
LSE:AZN
158.4
23%
6.9
CH
Novartis AG
SIX:NOVN
14.6
12%
1.2
US
Merck & Co Inc
NYSE:MRK
11
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
10.8
1%
10.8
IE
E
Endo International PLC
LSE:0Y5F
805.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.4
8%
1.3